User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

10291

Interactions with Platform & by Email *

INTERACTIONS

1235

Unique # Participated *

PARTICIPANTS

309

Responses Validated *

VALIDATIONS

33

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Allergy – A Global Perspective.....II-1
Allergy Prevalence.....II-1
Allergy - A US Perspective.....II-1
Allergy Prevalence.....II-1
1$105
   Market Overview.....II-2
Market Outlook.....II-2
Manufacturers Leverage Opportunity, Announce New Product Launches.....II-2
1$105
   Zyrtec’ Move to OTC Aisles Perks Up OTC Sales.....II-3
Allergy Patients Turn to Complimentary Medicine.....II-3
Leading Allergy Products.....II-3
1$105
   Table 1: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine Products by New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-41$350
   Table 2: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine + Decongestant Combination Products by New Prescription for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-51$350
   Table 3: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Total Prescriptions (in thousands) for 2007 and 2008 (includes corresponding Graph/Chart).....II-61$350
   Table 4: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Value Sales for 2007 and 2008 (includes corresponding Graph/Chart).....II-71$350
   Allergy: Definition.....II-8
Causes/ Factors.....II-8
Symptoms/ Triggers.....II-8
1$105
   Allergic Rhinitis – A Common Allergy.....II-9
Types of Allergic Rhinitis.....II-9
Diagnosis of Allergic Rhinitis.....II-9
Treatment of Allergy.....II-9
1$105
   Antihistamines.....II-10
Antihistamines - List of Select Generic Formulations and Products.....II-10
1$105
   Risks/ Side Effects.....II-11
Decongestants.....II-11
Decongestants - List of Select Generic Formulations and Products.....II-11
1$105
   Decongestant + Antihistamine - List of Select Generic Formulations and
  Products.....II-12
Risks/ Side Effects.....II-12
Corticosteroids.....II-12
1$105
   Intranasal Corticosteroids - List of Select Generic Formulations and
  Products.....II-13
Side Effects.....II-13
Allergy Shots.....II-13
Other Medicines.....II-13
Sodium Cromoglycate.....II-13
1$105
   Cromolyn Sodium.....II-14
Leukotriene Modifiers.....II-14
Glucocorticoids.....II-14
Leading Allergy Drugs.....II-14
Claritin.....II-14
Zyrtec.....II-14
1$105
   Benadryl.....II-15
Pollinex® Quattro.....II-15
Cortaid.....II-15
Visine-A.....II-15
Ocean Sinus Irrigation.....II-15
Crolom Eye Drops.....II-15
1$105
   McNeil Consumer Healthcare Launches Zyrtec for Children.....II-16
Cobalis Announces Online Launch of Anti-allergy Product.....II-16
Collegium Pharmaceutical Obtains FDA Approval for AllerNaze.....II-16
1$105
   Sanofi-aventis and UCB Win NDA Approval for Xyzal Oral Solution.....II-17
Sepracor Launches Omnaris Nasal Spray for Seasonal and Perennial Allergies.....II-17
1$105
   Sanofi Aventis Launches Allegra Orally Disintegrating Tablets.....II-18
Ranbaxy Wins FDA Approval for Generic Zyrtec.....II-18
Wockhardt Introduces Generic Cetirizine Tablets.....II-18
Hi-Tech Pharmacal Receives FDA Approval for Fluticasone Propionate.....II-18
Boca Pharmacal Wins FDA Approval for Palgic’s Generic Product.....II-18
1$105
   Ranbaxy Receives FDA Approval for Cetirizine Hydrochloride Oral Solution.....II-19
Perrigo and Teva Receive FDA Approval for Zyrtec-D.....II-19
Sanofi-aventis Receives FDA Approval for Nasacort AQ® Nasal Spray.....II-19
Sanofi-aventis and UCB Introduce Xyzal Anti-allergy Medication.....II-19
Sanofi-aventis Wins FDA Approval for Allegra® Oral Suspension.....II-19
1$105
   Matrixx Launches Zicam Multi-Symptom Cold & Flu Relief Products.....II-20
Ranbaxy Receives Approval to Market Claritin Reditabs’ Generic.....II-20
Procter & Gamble Introduces Nyquil D.....II-20
Leiner to Launch Naproxen Cold & Sinus Private Label Allergy Products.....II-20
1$105
   Merck Announces Business Merger Plan with Schering-Plough.....II-21
Hi-Tech Pharmacal to Acquire ECR Pharmaceuticals.....II-21
IBT Laboratories and ViraCor Announce Merger Plan.....II-21
1$105
   Lupin Acquires Rights to Collegium’s Intra-nasal Steroid.....II-22
Cobalis and Melodic Sign Agreement for PreHistin.....II-22
Patheon Receives Contract to Commercialize Allergy Drugs.....II-22
1$105
   Boehringer Ingelheim Signs Agreement for Actimis Acquisition.....II-23
Perrigo Acquires US Rights to Levocetirizine Tablets.....II-23
Sciele Pharma Acquires Verus Pharmaceuticals’ Allergy Injection.....II-23
1$105
   Sanofi-Aventis and Johns Hopkins University Division Sign Agreement.....II-24
Pipex Announces Effective Pharmaceuticals Acquisition.....II-24
Meda to Take Over American Company, MedPointe.....II-24
Private Group Proposes to Acquire Majority Interest in Inyx.....II-24
1$105
   Collegium Pharmaceutical, Inc......II-25
McNeil Consumer Healthcare.....II-25
Meda Pharmaceuticals, Inc......II-25
Novartis Consumer Healthcare, Inc......II-25
1$105
   Schering-Plough Corp......II-26
Sepracor, Inc......II-26
1$105
   Vicks.....II-271$105
   Table 5: US Recent Past, Current & Future Analysis for Allergy Drugs by Product Segment - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-281$350
   Table 6: US Historic Review for Allergy Drugs by Product Segment - Prescription Antihistamines, Prescription Corticosteroid, and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-291$350
   Table 7: US 15-Year Perspective for Allergy Drugs by Product Segment - Percentage Breakdown of Annual Value Sales for Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-301$350
   Allergy – Overview.....III-1
Strategic Corporate Developments.....III-1
2$210
   Allergy – Overview.....III-3
Product Approvals.....III-3
1$105
   Allergy - Prevalence.....III-4
United Kingdom.....III-4
Allergy – Overview.....III-4
Russia.....III-4
Allergy – Overview.....III-4
Product Launch.....III-4
1$105
   Strategic Corporate Developments.....III-5
Select Players.....III-5
3$175
   Allergy – Overview.....III-8
Australia and New Zealand.....III-8
China.....III-8
Market Overview.....III-8
1$105
   OTC Medications – A Small, But Growing Market.....III-9
Market Analytics.....III-9
Table 8: Chinese Recent Past, Current & Future Analysis for Allergy Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-9
1$200
   India.....III-10
Market Overview.....III-10
Malaysia.....III-10
Allergy – Overview.....III-10
1$105
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com